New SCOPE Data Put ACURATE neo on the Back Foot Again

New SCOPE Data Put ACURATE neo on the Back Foot Again

Patrice Wendling

October 21, 2020

0

ACURATE neo's (Boston Scientific) place in the treatment of severe aortic stenosis is unclear after failing to show noninferiority in a head-to-head comparison with another self-expanding, supra-annular transcatheter valve and reporting lackluster outcomes at 1 year in the SCOPE I trial.

The valve stumbled last year in SCOPE I when it did not establish noninferiority when compared with the balloon-expandable intra-annular Sapien 3 (Edwards Lifesciences) valve at 30 days.

In the SCOPE II trial, the ACURATE neo took on the self-expanding CoreValve Evolut (Medtronic) in 796 older adults (mean age, 83 years; 67.5% women) with symptomatic severe aortic stenosis (STS-PROM score, 4.6%).

The primary endpoint of all-cause death or any stroke at 1 year occurred in 15.8% of ACURATE neo patients and 13.9% of CoreValve patients in an intention-to-treat analysis (one-sided upper 95% confidence limit, 6.1%; P = .0549 for noninferiority).

In a per-protocol analysis, the primary endpoint occurred in 15.3% and 14.3%, respectively (one-sided upper 95% confidence limit 5.4%; P = .0314 for noninferiority).

The study could not claim noninferiority, however, because the protocol required both analyses to show noninferiority at a margin of 6%, explained Corrado Tamburino, MD, PhD, University of Catania, Italy.

The findings were presented in a late-breaking clinical trial session at the virtual meeting of Transcatheter Cardiovascular Therapeutics (TCT) 2020 and

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....